Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 4/20 | 0.58 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.52 |
| ▸ | ATR | Q13535 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12775220 | 0.90 | HPGDS (0.60) | HPGDSUSP30DYRK1AATRHDAC4 | |
| SCHEMBL14190101 | 0.89 | HPGDS (0.59) | HPGDSUSP30NPC1RXFP1SSTR5 | |
| SCHEMBL2069780 | 0.88 | HPGDS (0.69) | HPGDSUSP30DYRK1AATRNPC1 | |
| SCHEMBL2072921 | 0.87 | HPGDS (0.74) | HPGDSUSP30DYRK1AATR | |
| SCHEMBL1543098 | 0.85 | NPC1 (0.68) | HPGDSNPC1RXFP1PTPN1PTPN6 | |
| SCHEMBL12775223 | 0.84 | HPGDS (0.52) | HPGDSUSP30DYRK1A | |
| SCHEMBL2070758 | 0.84 | HPGDS (0.54) | HPGDSUSP30SSTR5KMT2A | |
| SCHEMBL12776654 | 0.84 | HPGDS (0.52) | HPGDSUSP30DYRK1AEGLN1 | |
| SCHEMBL2072683 | 0.84 | HPGDS (0.83) | HPGDSUSP30SSTR5EGLN1MCHR1 | |
| SCHEMBL4749226 | 0.84 | NPC1 (0.67) | NPC1HDAC4HDAC6MCHR1SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | HPGDS 984/4885USP30 4416/4885DYRK1A 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.